C-Rad Bilan de santé

Santé financière contrôle des critères 6/6

C-Rad possède un total de capitaux propres de SEK310.2M et une dette totale de SEK0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont SEK450.1M et de SEK139.9M. L'EBIT de C-Rad est SEK66.4M ce qui fait que son ratio de couverture des intérêts -13.8. Elle dispose de liquidités et de placements à court terme de SEK118.7M.

Informations clés

Ratio d'endettement

SEK 0

Dette

Ratio de couverture des intérêts	-13.8x
Argent liquide	SEK 118.70m
Fonds propres	SEK 310.20m
Total du passif	SEK 139.90m
Total des actifs	SEK 450.10m

Mises à jour récentes de la santé financière

Pas de mise à jour

Recent updates

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de 0R44 ( SEK399.4M ) dépassent ses passifs à court terme ( SEK127.2M ).

Passif à long terme: Les actifs à court terme de 0R44 ( SEK399.4M ) dépassent ses passifs à long terme ( SEK12.7M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: 0R44 est sans dette.

Réduire la dette: 0R44 n'avait aucune dette il y a 5 ans.

Couverture de la dette: 0R44 n'a pas de dette, elle n'a donc pas besoin d'être couverte par le flux de trésorerie opérationnel.

Couverture des intérêts: 0R44 n'a aucune dette, par conséquent la couverture des paiements d'intérêts n'est pas un problème.

C-Rad Bilan de santé

Santé financière contrôle des critères 6/6

Informations clés

Mises à jour récentes de la santé financière

Recent updates

C-Rad AB (publ) to Report Q3, 2025 Results on Oct 23, 2025

Independent Director recently bought kr190k worth of stock

New minor risk - Market cap size

Third quarter 2024 earnings released: EPS: kr0.45 (vs kr0.32 in 3Q 2023)

CEO & President recently bought kr85k worth of stock

Second quarter 2024 earnings released: EPS: kr0.31 (vs kr0.16 in 2Q 2023)

Full year 2023 earnings released: EPS: kr1.05 (vs kr0.22 in FY 2022)

C-Rad AB (publ) Appoints Mats Thorén as Board Member

C-Rad AB (publ) to Report Fiscal Year 2023 Results on Apr 23, 2024

Full year 2023 earnings released: EPS: kr1.36 (vs kr0.22 in FY 2022)

C-Rad AB (publ) to Report Q3, 2024 Results on Oct 23, 2024

Third quarter 2023 earnings released

Investor sentiment improves as stock rises 17%

Less than half of directors are independent

C-Rad AB (Publ) Announces Former Employee Appeals Verdict from the Patent and Market Court of Appeal

New major risk - Earnings quality

C-Rad AB (publ) to Demonstrate Enhancements in Surface Guided Solutions for Advanced Radiotherapy Treatments at AAPM

Second quarter 2023 earnings released

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

C-Rad AB (publ) to Report Fiscal Year 2022 Final Results on Apr 06, 2023

C-Rad AB (Publ) Appoints Christoffer Herou as CFO

C-Rad AB (Publ) Announces CEO Changes

C-Rad AB (publ) Announces CFO Changes

C-Rad AB (publ) to Report Q3, 2023 Results on Oct 27, 2023

C-RAD Launches New Updated eDucation Portal as an Online Platform

Second quarter 2022 earnings released

Henrik Bergentoft Resigns as CFO of C-RAD

C-Rad Announces CEO Changes

Insufficient new directors

Insufficient new directors

C-Rad AB (publ) to Report Q3, 2022 Results on Oct 28, 2022

C-Rad Achieves Another Milestone Ensuring the Availability of SGRT, the Standard of Care for Radiotherapy

Third quarter 2021 earnings released

Chief Operating Officer recently sold kr625k worth of stock

Second quarter 2021 earnings released

C-Rad AB (publ) Announces The Patent and Market Court Rejected Former Employee Claim for Compensation

The Patent and Market Court of Appeal Issues Judgement Confirming C-Rad's Entitlement to Beamocular's Invention

Full year 2020 earnings released: EPS kr0.43 (vs kr0.45 loss in FY 2019)

C-RAD and Alliance Radiation Oncology Announce That Alliance Has Become the First Center in the Greater Northshore Area to Integrate C-Rad

C-Rad and With-Global Engages in a Partnership for the South Korean Market

C-RAD Receives Order for Proton Cancer Treatment Centers in the US

Shenzhen Proton Therapy Treatment Center Selects C-Rad Catalyst™ System

C-Rad AB (publ) to Report Q2, 2021 Results on Jul 29, 2021

Shanghai Proton and Heavy Ion Hospital Decides for C-Rad Sigrt Solution

Australian Customers Select C-RAD’s Cutting Edge SIGRT Solution

C-Rad AB Receives SEK 11 Million Order for Cutting Edge SIGRT Solution by DTZ in Berlin

Independent Director recently sold kr672.4k worth of stock

Independent Director recently bought kr1.7m worth of stock

Independent Director recently sold kr3.4m worth of stock

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Découvrir des entreprises saines